News

Yale researchers across disciplines are using single cell technologies to profile various kinds of cells that exist together in both healthy and diseased organs and create the most detailed blueprints of diseases to date, as well as to better understand how various cells develop over time and interact with one another.

A new class of cancer drugs is being investigated to target drug resistant prostate, lung, and colorectal cancers. Findings from Yale scientists...

Crews was awarded the medal for his pioneering research that launched the pharmaceutical field of targeted protein degradation.

The evening of May 10, 2022, the Friends of Cancer Research held their 25th Anniversary Dinner Celebration at the Four Seasons Hotel in Washington, DC. Roy S. Herbst, MD, PhD, was recognized at the event for his contributions in lung cancer as one of the foremost leaders in lung cancer treatment and research.

OncLive®, the nation’s leading multimedia resource for oncology professionals, is pleased to announce the winners of the 10th annual Giants of Cancer Care® awards.

Connecticut Magazine has named 87 Yale Cancer Center and Smilow Cancer Hospital physicians to its 2022 Best Doctors guide.

Mark Lemmon, a professor of pharmacology, molecular biophysics and biochemistry at Yale and co-director of the university's Cancer Biology Institute, was appointed deputy director of the Yale Cancer Center, a clinical and research institute, in February

Roy S. Herbst, MD, PhD, has been appointed Chair of the American Association for Cancer Research (AACR) Scientific Policy and Government Affairs Committee; the appointment became effective at the AACR Annual Meeting earlier this week in New Orleans.

Yale scientists have discovered that a protein known as augmentor-alpha regulates body weight in mice, an insight that could lead to new treatments for metabolic disorders.